HOLDINGS
CREDENCE MEDSYSTEMS
Pharma Services/Drug Delivery
Credence MedSystems is an advanced drug delivery technology and pharmaceutical services company focused on transforming the commercialization of injectable therapies through innovative, differentiated delivery systems for pharmaceutical and biotechnology manufacturers. Headquartered in Silicon Valley in Menlo Park, California, the company has emerged as one of the industry’s leading innovators in injectable drug delivery devices, developing proprietary platforms that address some of the most important challenges facing modern biologics, specialty pharmaceuticals, self administered therapies, ophthalmics, vaccines, and high viscosity injectable formulations.
Founded in 2013, Credence MedSystems has built a highly differentiated position at the intersection of pharmaceutical delivery systems, medical technology, biologics commercialization, patient safety, and advanced injectable therapeutics. The company’s mission is centered on providing pharmaceutical manufacturers with innovative drug delivery solutions capable of solving unmet clinical, operational, manufacturing, and patient usability challenges across a rapidly evolving global healthcare landscape. As biologics, specialty injectables, complex formulations, and self administered therapies continue to drive growth throughout the pharmaceutical industry, Credence has strategically positioned itself as a critical enabling partner for drug manufacturers seeking to modernize injectable delivery while minimizing commercialization risk and preserving existing validated manufacturing ecosystems.
At the core of the company’s strategy is its highly differentiated Innovation Without Change® philosophy, which has become one of the defining value propositions of the Credence platform. Rather than forcing pharmaceutical companies to redesign fill finish operations, manufacturing infrastructure, supply chains, or validated primary packaging systems, Credence enables manufacturers to integrate advanced safety, usability, and delivery functionality into existing prefilled syringe architectures. This significantly reduces implementation hurdles while allowing pharmaceutical companies to achieve meaningful product differentiation, improved patient experiences, enhanced adherence, and increased safety without introducing unnecessary operational complexity or regulatory disruption.
Credence MedSystems is widely recognized for its flagship Companion® Safety Syringe System, an award winning injectable delivery platform that has helped redefine the commercialization pathway for injectable therapies. The Companion system integrates advanced usability features, automatic passive needle retraction, reuse prevention, end of dose cues, operational efficiency enhancements, and sustainability advantages into a highly scalable syringe platform. The system has been specifically engineered to preserve compatibility with industry standard syringe barrels and established pharmaceutical manufacturing processes, allowing biopharmaceutical manufacturers to accelerate time to market while minimizing development costs and implementation risk. The platform has consistently demonstrated strong end user preference characteristics while addressing critical industry concerns surrounding safety, usability, waste reduction, and patient adherence.
The company has strategically expanded its technology portfolio into multiple high value injectable therapy markets through a broad family of proprietary delivery systems and enabling technologies. These include advanced Dual Chamber syringe platforms for reconstitution and sequential injection applications, Isolation Valve technologies designed to eliminate needle clogging associated with high concentration biologics and suspension formulations, Micro Dose™ systems for precision ophthalmic applications, Multi Site™ injection systems for toxin and filler applications, and Force Assist™ technologies for high viscosity injectables. Collectively, these platforms address many of the most significant challenges facing modern injectable drug development, including formulation stability, room temperature storage requirements, self administration usability, injection force reduction, accurate low volume dosing, and biologic delivery optimization.
The company’s Dual Chamber platform represents a particularly important strategic opportunity within the rapidly expanding biologics and advanced therapeutics markets. The system enables one step mixing and injection while supporting liquid, powder, and lyophilized drug formulations that require constituent separation during storage. The platform incorporates advanced safety functionality, passive needle retraction, smart reuse prevention, intuitive usability, and end of dose feedback cues, enabling safer and more effective administration by clinicians, caregivers, and self injectors alike. Credence’s Dual Chamber technologies are increasingly relevant as pharmaceutical manufacturers pursue more complex biologic therapies requiring improved stability, simplified reconstitution, and expanded home administration capabilities.
Credence has also developed specialized delivery technologies targeting several of the fastest growing injectable therapy sectors globally, including ophthalmology, medical aesthetics, and therapeutic toxins. Its Micro Dose™ syringe platform enables highly precise micro dosing for ophthalmic applications while reducing overdosing risk, improving usability, and maintaining compatibility with existing prefilled syringe systems. The company’s Multi Site™ Injection System and Force Assist™ technologies are designed to improve procedural efficiency, reduce injection force requirements, simplify administration of viscous formulations, and provide enhanced dosing precision across aesthetic and therapeutic applications. These capabilities position Credence to participate in several rapidly expanding specialty pharmaceutical markets where device innovation and patient experience are becoming increasingly important competitive differentiators.
One of Credence MedSystems’ most significant strategic strengths is its extensive intellectual property estate, which provides meaningful barriers to entry across multiple injectable delivery categories. As of December 2025, the company had built a substantial global IP portfolio consisting of more than 260 active United States and international patent cases and more than 150 issued or allowed patents covering systems, methods, apparatus, and injectable delivery technologies across more than 28 unique devices. International patent filings span major pharmaceutical markets including Europe, Japan, China, India, Canada, and Israel. This broad and expanding intellectual property foundation positions Credence as a potentially important long term platform company within the global injectable therapeutics ecosystem.
The company has also made substantial investments in manufacturing readiness, scalability, and commercial infrastructure. Credence operates advanced research laboratories, pilot manufacturing facilities, and GMP clinical manufacturing capabilities designed to support pharmaceutical development programs, clinical supply, and large scale commercial deployment. Its manufacturing strategy includes flexible clinical production systems and future high volume automated manufacturing capabilities capable of supporting tens of millions of units annually. Credence has also collaborated with Phillips Medisize on manufacturing scale up initiatives, further strengthening its ability to support large pharmaceutical commercialization programs.
Credence MedSystems has attracted significant strategic validation from leading global pharmaceutical, medical technology, and healthcare organizations. The company has received strategic investments from Novartis and Molex through Phillips Medisize, reflecting strong industry confidence in the commercial relevance and scalability of Credence’s technology platforms. Novartis specifically invested to support the development, manufacturing scale up, and commercialization of Credence’s innovative injectable delivery systems for pharmaceutical applications.
Credence also maintains strategic collaborations with SCHOTT Pharma, one of the world’s leading providers of pharmaceutical containment and delivery systems. SCHOTT’s expertise in prefillable syringes, drug containment, and injectable delivery infrastructure aligns closely with Credence’s commercialization strategy of preserving validated pharmaceutical components while enabling advanced delivery innovation.
In addition, Credence MedSystems has received grants and support from the Bill & Melinda Gates Foundation in recognition of the company’s potential contributions to global health and vaccine delivery initiatives. The Gates Foundation supported development of Credence’s Dual Chamber Reconstitution Syringe platform for use in developing nations and global healthcare environments where safe, intuitive, low complexity drug and vaccine delivery systems are critically important. These initiatives were designed to improve the administration of therapies requiring dried storage and point of care reconstitution while reducing contamination risks, dosing errors, and needlestick exposure in low resource healthcare environments.
The company is led by a seasoned management and leadership team with extensive experience founding, scaling, and commercializing successful medical technology and drug delivery companies. Credence’s leadership foundation has played a critical role in positioning the company as a strategic innovation platform capable of serving global pharmaceutical manufacturers across multiple injectable therapy categories.
From an industry and investment perspective, Credence MedSystems represents a highly differentiated healthcare technology platform operating within several of the pharmaceutical industry’s most important and fastest growing markets, including biologics delivery, self administration systems, injectable therapeutics, ophthalmics, vaccine delivery, medical aesthetics, and specialty pharmaceuticals. The company combines advanced engineering, scalable pharmaceutical integration capabilities, robust intellectual property, manufacturing readiness, and strategic pharmaceutical partnerships into a platform designed to address the increasing complexity of modern injectable therapies. As the global healthcare industry continues transitioning toward biologics, precision therapeutics, home administration, and patient centric delivery systems, Credence MedSystems is strategically positioned as an important enabling technology company within the future of injectable drug delivery and pharmaceutical commercialization.
